Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1
5-Year Impact Factor – 2.2
Scopus CiteScore – 3.4 (CiteScore Tracker 3.7)
Index Copernicus  – 161.11; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2016, vol. 25, nr 5, September-October, p. 971–975

doi: 10.17219/acem/36460

Publication type: review

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

MicroRNAs in the Occurrence and Development of Primary Hepatocellular Carcinoma

Jie Xu1,B,C,D,E, Ji Li2,B, Tai-Hao Zheng3,B, Lian Bai1,B, Zuo-Jin Liu2,E,F

1 Department of Gastrointestinal Surgery, Yongchuan Hospital, Chongqing Medical University, Chongqing, China

2 Department of Hepatobiliary Surgery, Second Affiliated Hospital of Chongqing Medical University, Chongqing, China

3 Department of Oncology, Yongchuan Hospital, Chongqing Medical University, Chongqing, China

Abstract

Hepatocellular carcinoma is one of the deadliest types of cancer. Despite improvements in treatment over the past few decades, patient survival remains poor and there is an urgent need for development of targeted therapies. MicroRNAs represent a class of small RNAs, frequently deregulated in human malignancies. We are reviewing the role of microRNA in the development of primary hepatocellular carcinoma and its use as a biomarker for early diagnosis and clinical treatment. First, we describe the current incidence and possible causes of the incidence of hepatocellular carcinoma, followed by the introduction of microRNA synthesis, maturation and function, and finally we explain the role of microRNA in the development of hepatocellular carcinoma and its clinical value as a biological marker in the diagnosis and treatment of liver cancer. A comprehensive analysis of cellular microRNA is a benefit for early diagnosis of hepatocellular carcinoma and early clinical intervention, and microRNA is considered by some to be a key target of gene therapy to control the occurrence and development of hepatocellular carcinoma..

Key words

microRNA, HCC, occurrence, development, biomarkers

References (36)

  1. Levrero M: Viral hepatitis and liver cancer: The case of hepatitis C. Oncogene 2006, 25, 3834–3847.
  2. Lee JS, Chu IS, Heo J, Calvisi DF, Sun Z, Roskams T, Durnez A, Demetris AJ, Thorgeirsson SS: Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004, 40, 667–676.
  3. Jiang J, Gusev Y, Aderca I, Mettler TA, Nagorney DM, Brackett DJ, Roberts LR, Schmitggen TD: Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res 2008, 14, 419–427.
  4. Roberts LR, Gores GJ: Hepatocellular carcinoma: Molecular pathways and new therapeutic targets. Semin Liver Dis 2005, 25, 212–225.
  5. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61, 69–90.
  6. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP: The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. Hepatology 2006, 45, 529–538.
  7. Sanyal AJ, Yoon SK, Lencioni R: The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist 2010, 15, 14–22.
  8. Kim VN, Han J, Siomi MC: Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol 2009, 10, 126–139.
  9. Kim VN: MicroRNA biogenesis: Coordinated cropping and dicing. Nat Rev Mol Cell Biol 2005, 6, 376–385.
  10. Kim Y, Kim VN: MicroRNA factory: RISC assembly from precursor microRNAs. Mol Cell 2012, 25, 46, 384–386.
  11. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T: Identification of novel genes coding for small expressed RNAs. Science 2001, 294, 853–858.
  12. Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004, 116, 281–297.
  13. Lewis BP, Burge CB, Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120, 15–20.
  14. Lee YS, Kim HK, Chung S, Kim KS, Dutta A: Depletion of human micro-RNA miR-125b reveals that it is critical for the proliferation of differentiated cells but not for the down-regulation of putative targets during differentiation. J Biol Chem 2005, 280, 16635–16641.
  15. Negrini M, Gramantieri L, Sabbioni S, Croce CM: microRNA involvement in hepatocellular carcinoma. Anticancer Agents Med Chem 2011, 11, 500–521.
  16. Gramantieri L, Ferracin M, Fornari F, Veronese A, Sabbioni S, Liu CG: Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res 2007, 67, 6092–6099.
  17. Kutay H, Bai S, Datta J, Motiwala T, Pogribny I, Frankel W: Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem 2006, 99, 671–678.
  18. Nassirpour R, Mehta PP, Yin MJ: miR-122 regulates tumorigenesis in hepatocellular carcinoma by targeting AKT3. PLoS One 2013, 8.
  19. Bai S, Nasser MW, Wang B, Hsu SH, Datta J, Kutay H: MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J Biol Chem 2009, 284, 32015–32027.
  20. Hou J, Lin L, Zhou W: Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell 2011, 19, 232–243.
  21. Su H, Yang JR, Xu T, Huang J, Xu L, Yuan Y: MicroRNA-101 down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res 2009, 69, 1135–1142.
  22. Pineau P, Volinia S, McJunkin K, Marchio A, Battiston C, Terris B: miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci USA 2010, 107, 264–269.
  23. Zhang Z, Li Z, Gao C, Chen P, Chen J, Liu W: miR-21 plays a pivotal role in gastric cancer pathogenesis and progression. Lab Invest 2008, 88, 1358–1366.
  24. Huang S, He X: The role of microRNAs in liver cancer progression. Br J Cancer 2011, 104, 235–240.
  25. Wu J1, Zhang XJ, Shi KQ, Chen YP, Ren YF, Song YJ, Li G, Xue YF, Fang YX, Deng ZJ, Xu X, Gao J, Tang KF: Hepatitis B surface antigen inhibits MICA and MICB expression via induction of cellular miRNAs in hepatocellular carcinoma cells. Carcinogenesis 2014, 35, 155–163.
  26. Zha R, Guo W, Zhang Z, Qiu Z, Wang Q: Genome-wide screening identified that mir-134 acts as a metastasis suppressor by targeting integrin beta 1 in hepatocellular carcinoma. PLoS One 2014, 9, e87665.
  27. Garofalo M, Di Leva G, Romano G, Nuovo G, Suh SS, Ngankeu A, Taccioli C, Pichiorri F, Alder H, Secchiero P, Gasparini P, Gonelli A, Costinean S, Acunzo M, Condorelli G, Croce CM: miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 2009, 16, 498–509.
  28. Wong QW, Ching AK, Chan AW, Choy KW, To KF, Lai PB, Wong N: MiR-222 overexpression confers cell migratory advantages in hepatocellular carcinoma through enhancing AKT signaling. Clin Cancer Res 2010, 16, 867–875.
  29. Zhang X, Liu S, Hu T, Liu S, He Y, Sun S: Up-regulated microRNA-143 transcribed by nuclear factor kappa B enhances hepatocarcinoma metastasis by repressing fibronectin expression. Hepatology 2009, 50, 490–499.
  30. Yang F, Yin Y, Wang F, Wang Y, Zhang L, Tang Y, Sun S: miR-17-5p promotes migration of human hepatocellular carcinoma cells through the p38 mitogen-activated protein kinase-heat shock protein 27 pathway. Hepatology 2010, 51, 1614–1623.
  31. Toffanin S, Hoshida Y, Lachenmayer A: MicroRNA based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology 2011, 140, 1618–1628.
  32. Li LM, Hu ZB, Zhou ZX, Chen X, Liu FY, Zhang JF, Shen HB, Zhang CY, Zen K: Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res 2010, 70, 9798–9807.
  33. Tsai WC, Hsu PW, Lai TC, Chau GY, Lin CW: MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology 2009, 49, 1571–1582.
  34. Lang Q, Ling C: MiR-124 suppresses cell proliferation in hepatocellular carcinoma by targeting PIK3CA. Biochem Biophys Res Commun 2012, 426, 247–252.
  35. Park JK, Kogure T, Nuovo GJ, Jiang J, He L: miR-221 silencing blocks hepatocellular carcinoma and promotes survival. Cancer Res 2011, 71, 7608–7616.
  36. Callegari E, Elamin BK, Giannone F, Milazzo M, Altavilla G: Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model. Hepatology 2012, 56, 1025–1033.
© Wroclaw Medical University